Genentech seeks expanded FDA approval for Avastin

12/3/2007 | Bloomberg

Genentech has applied for regulatory approval to market Avastin as a treatment for breast cancer. The move follows a successful clinical trial of Avastin, in which 722 breast cancer patients who took the drug with the chemotherapy agent paclitaxel had stable tumors for an average of 11 months, compared to six months in the control group. FDA advisers are scheduled to meet Wednesday to consider the company's request.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX